A4 cont. Type Culture Collection, now located at 10801 University Boulevard, Manassas, Virginia 20110-2209, on 3 November 1993, and assigned ATCC Accession No. ATCC HB 11483.

On page 60, please **delete** the footer entitled "5490A220.APP" on the bottom of the page.

In the Claims:

Please cancel claims 1-25, 28-30, 32, 34, and 36-58 without disclaimer or prejudice to the underlying subject matter.

Please amend claims 26, 27 and 31 as follows:

26. (Amended) The antibody of claim 31 that inhibits activation of $CD4^+$ T-cells.

27. (Amended) The monoclonal antibody of claim 31 that stimulates activation of $CD4^+$ T-cells.

A5 31. (Amended) A monoclonal antibody that is L106.

Please add new claims 59-77 as follows:

A6 59. A monoclonal antibody that specifically binds to an ACT-4-h-1 receptor polypeptide and is generated by hybridoma HBL106, deposited under ATCC Accession No. HB11483.

60. A fragment of an L106 antibody that specifically binds to an ACT-4-h-1 receptor polypeptide with a binding affinity of at least 10^7 M.

61. The fragment of claim 60, wherein said fragment is selected from the group consisting of a heavy chain, a light chain, a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment, a Fabc fragment, and a Fv fragment.

62. A monoclonal antibody produced by hybridoma HBL106, deposited under ATCC Accession No. HB11483.

A6 cont.

63. A cell of hybridoma HBL106, deposited under ATCC Accession No. HB11483.

Amt C4

64. A humanized antibody comprising a humanized heavy chain, wherein the humanized heavy chain comprises three complementarity determining regions corresponding to the complementarity determining regions of an L106 antibody heavy chain.

65. The humanized antibody of claim 64, wherein said humanized antibody specifically binds to an ACT-4-h-1 receptor polypeptide with a binding affinity that is within three-fold of the binding affinity of an L106 antibody.

66. A fragment of the humanized antibody of claim 64, wherein said fragment specifically binds to an ACT-4-h-1 receptor polypeptide.

Amt C5

67. A humanized antibody comprising a humanized light chain, wherein the humanized light chain comprises three complementarity determining regions corresponding to the complementarity determining regions of an L106 antibody light chain.

68. The humanized antibody of claim 67, wherein said humanized antibody specifically binds to an ACT-4-h-1 receptor polypeptide with a binding affinity that is within three-fold of the binding affinity of an L106 antibody.

69. A fragment of the humanized antibody of claim 67, wherein said fragment specifically binds to an ACT-4-h-1 receptor polypeptide.

A6

70. A humanized antibody comprising (a) a humanized light chain, wherein the humanized light chain comprises three complementarity determining regions corresponding to the complementarity determining regions of an L106 antibody light chain, and (b) a humanized heavy chain, wherein the humanized heavy chain comprises three complementarity determining regions corresponding to the complementarity determining regions of an L106 antibody heavy chain.

A6 cont.

71. The humanized antibody of claim 70, wherein said humanized antibody specifically binds to an ACT-4-h-1 receptor polypeptide with a binding affinity that is within three-fold of the binding affinity of an L106 antibody.

72. A fragment of the humanized antibody of claim 70, wherein said fragment specifically binds to an ACT-4-h-1 receptor polypeptide.

73. A method of detecting activated $CD4^+$ T-cells in a sample, comprising:

contacting the sample and an L106 antibody; and

detecting specific binding between the sample and the L106 antibody to reveal the presence of activated $CD4^+$ T-cells in the sample.

74. The method of 73, wherein said method is a method of detecting activated $CD4^+$ T-cells in a tissue sample.

75. The method of 73, wherein said method is a method of detecting activated $CD4^+$ T-cells in a blood sample.

76. A method of detecting activated $CD4^+$ T-cells in a patient, comprising:

administering a diagnostic reagent comprising L106 antibody to a patient; and